The lingering mysteries of metastatic recurrence in breast cancer

被引:383
作者
Riggio, Alessandra I. [1 ]
Varley, Katherine E. [1 ]
Welm, Alana L. [1 ]
机构
[1] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA
关键词
CIRCULATING TUMOR-CELLS; MINIMAL RESIDUAL DISEASE; BONE-MARROW; FOLLOW-UP; EARLY DISSEMINATION; ESTROGEN-RECEPTOR; PROGNOSTIC IMPACT; AMERICAN SOCIETY; EXTRACELLULAR-MATRIX; MOLECULAR PORTRAITS;
D O I
10.1038/s41416-020-01161-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a protracted period of undetectable disease following surgery or systemic therapy, owing to relapse or recurrence. In the case of breast cancer, metastatic relapse can occur months to decades after initial diagnosis and treatment. In this review, we provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.
引用
收藏
页码:13 / 26
页数:14
相关论文
共 169 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis [J].
Aceto, Nicola ;
Bardia, Aditya ;
Miyamoto, David T. ;
Donaldson, Maria C. ;
Wittner, Ben S. ;
Spencer, Joel A. ;
Yu, Min ;
Pely, Adam ;
Engstrom, Amanda ;
Zhu, Huili ;
Brannigan, Brian W. ;
Kapur, Ravi ;
Stott, Shannon L. ;
Shioda, Toshi ;
Ramaswamy, Sridhar ;
Ting, David T. ;
Lin, Charles P. ;
Toner, Mehmet ;
Haber, Daniel A. ;
Maheswaran, Shyamala .
CELL, 2014, 158 (05) :1110-1122
[3]   Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer [J].
Aggelis, Vassilis ;
Johnston, Stephen R. D. .
DRUGS, 2019, 79 (17) :1849-1866
[4]   Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo [J].
Aguirre-Ghiso, JA ;
Liu, D ;
Mignatti, A ;
Kovalski, K ;
Ossowski, L .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (04) :863-879
[5]  
Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
[6]   Models, mechanisms and clinical evidence for cancer dormancy [J].
Aguirre-Ghiso, Julio A. .
NATURE REVIEWS CANCER, 2007, 7 (11) :834-846
[7]   Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice [J].
Albrengues, Jean ;
Shields, Mario A. ;
Ng, David ;
Park, Chun Gwon ;
Ambrico, Alexandra ;
Poindexter, Morgan E. ;
Upadhyay, Priya ;
Uyeminami, Dale L. ;
Pommier, Arnaud ;
Kuttner, Victoria ;
Bruzas, Emilis ;
Maiorino, Laura ;
Bautista, Carmelita ;
Carmona, Ellese M. ;
Gimotty, Phyllis A. ;
Fearon, Douglas T. ;
Chang, Kenneth ;
Lyons, Scott K. ;
Pinkerton, Kent E. ;
Trotman, Lloyd C. ;
Goldberg, Michael S. ;
Yeh, Johannes T. -H. ;
Egeblad, Mikala .
SCIENCE, 2018, 361 (6409) :1353-+
[8]   Transcriptional Switch of Dormant Tumors to Fast-Growing Angiogenic Phenotype [J].
Almog, Nava ;
Ma, Lili ;
Raychowdhury, Raktima ;
Schwager, Christian ;
Erber, Ralf ;
Short, Sarah ;
Hlatky, Lynn ;
Vajkoczy, Peter ;
Huber, Peter E. ;
Folkman, Judah ;
Abdollahi, Amir .
CANCER RESEARCH, 2009, 69 (03) :836-844
[9]  
American Cancer Society, 2019, Cancer treatment and survivorship facts and figures 2019-2021, DOI DOI 10.1080/15398285.2012.701177
[10]  
[Anonymous], 2007, J ONCOL PRACT, V3, P336, DOI [10.1200/JCO.2007.14.2364, 10.1200/JOP.0768504]